SCHEMBL4058788

SCHEMBL4058788

CCn1nc(-c2ccccc2)c(C(=O)NNC(C)=O)c(N)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.52
CSF1R P07333 1/20 0.51
FGFR1 P11362 1/20 0.51
FLT1 P17948 1/20 0.51
KDR P35968 1/20 0.51
CSNK1A1 P48729 1/20 0.51
CDK8 P49336 1/20 0.51
GSK3A P49840 1/20 0.51
GSK3B P49841 1/20 0.51
CDK5 Q00535 1/20 0.51
PRKCQ Q04759 1/20 0.51
LRRK2 Q5S007 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
DYRK1B Q9Y463 1/20 0.51
PDE4B Q07343 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.48
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
ADORA3 P0DMS8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032899 0.85 CSF1R (0.69) TP53CSF1RFGFR1FLT1KDR
SCHEMBL4051575 0.84 CSF1R (0.56) TP53CSF1RFGFR1FLT1KDR
SCHEMBL4053658 0.83 TP53 (0.55) TP53CSF1RFGFR1FLT1KDR
SCHEMBL4051848 0.82 TP53 (0.52) TP53CSF1RFGFR1FLT1KDR
SCHEMBL4708019 0.82 CSF1R (0.53) TP53CSF1RFGFR1FLT1KDR
SCHEMBL4051622 0.80 CSF1R (0.54) TP53CSF1RFGFR1FLT1KDR
SCHEMBL4049848 0.79 PDE4A (0.58) TP53CSF1RFGFR1FLT1KDR
SCHEMBL3029472 0.77 SMN1; SMN2 (0.48) TP53CSF1RFGFR1FLT1KDR
SCHEMBL4062432 0.75 PDE4B (0.47) TP53CSF1RFGFR1FLT1KDR
SCHEMBL3021825 0.74 KDR (0.53) TP53CSF1RFGFR1FLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511038-B2 Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors LABORATORIOS ALMIRALL S.A. (ES) 2009-03-31 US disclosed
US-20070197536-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-23 US disclosed
EP-1682519-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2006-07-26 EP disclosed
WO-2005049581-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL PRODESFARMA, S.A. (ES) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197536-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease PDE12, PDE4A, PDE7A TP53 4507/4885CSF1R 2518/4885FGFR1 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.